Botulinum toxin type B: An effective treatment for alleviating pain associated with cervical dystonia

Journal of Back and Musculoskeletal Rehabilitation

Volumn 16, Issue 1, 2002, Pages 3-9

  Lew, Mark F ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Botulinum toxin; Cervical dystonia; Efficacy; Pain

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DYSTONIA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE SPASM; NECK PAIN; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TORTICOLLIS; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 0036398823     PISSN: 10538127     EISSN: None     Source Type: Journal    
DOI: 10.3233/BMR-2002-16102     Document Type: Article

References (32)

1. M.A. Acquadro and G.E. Borodic, Treatment of myofascial pain with botulinum A toxin, Anesthesiology 80 (1994), 705-706.
2. S.S. Arnon, R. Schechter and T.V. Inglesby et al., Botulinum toxin as a biological weapon, JAMA 285 (2001), 1059-1070.
3. D. Boghen and M. Flanders, Effectiveness of botulinum toxin in the treatment of spasmodic torticollis, Eur Neurol 33 (1993), 199-203.
4. A. Brashear, M.F. Lew and D.D. Dykstra et al., Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia, Neurology 53 (1999), 1439-1446.
5. M.F. Brin, M.F. Lew and C.H. Adler et al., Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia, Neurology 53 (1999), 1431-1438.
6. J.E. Callaway, J.C. Arezzo and A.J. Grethlein, Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology, Sem Cut Med Surg 20 (2001), 127-136.
7. J. Chan, M.F. Brin and S. Fahn, Idiopathic cervical dystonia: clinical characteristics, Mov Disord 6 (1991), 119-126.
8. W.P. Cheshire, S.W. Abashian and.J.D. Mann, Botulinum toxin in the treatment of myofascial pain syndrome, Pain 59 (1994), 65-69.
9. Y. Choi, S.N. Raja, L.C. Moore and JR. Tobin, Neuropathic pain in rats is associated with altered nitric oxide synthase activity in neural tissue, J Neurol Sci 138 (1996), 14-20.
10. Conference report, clinical use of botulinum toxin, National Institutes of Health Consensus Development Conference statement, Arch Neural 48 (1991), 1294-1296.
11. E.S. Consky, A. Basinski and L. Belle et al., The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rate reliability (abstract), Neurology 40 (1991), 445.
12. E.S. Consky and A.E. Lang, Assessment of cervical dystonia: the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), in: Therapy with botulinum toxin, neurological disease and therapy series, (Vol. 25), J. Jankovic and M. Hallet, eds, Marcel Dekkar, New York, 1994, pp. 224-237.
13. P.A. Cullis, C.F. O'Brien and D.D. Truong et al., Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients, Adv Neurol 78 (1998), 227-230.
14. W.T. Dauer, R.E. Burke, P. Greene and S. Fahn, Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia, Brain 121 (1998), 547-560.
15. N. Giladi, The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site, J Neurol Sci 152 (1997), 132-135.
16. T. Gordh, R. Karlsten and J. Kristensen, Intervention with spinal NMDA, adenosine and NO systems for pain modulation, Ann Med 27 (1995), 229-234.
17. P. Greene, H. Shale and S. Fahn, Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs, Mov Disord 3 (1988), 46-60.
18. B.M. Guyer, Mechanism of botulinum toxin in the relief of chronic pain, Curr Rev Pain 3 (1999), 427-431.
19. P. Hambleton, Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use, J Neural 239 (1992), 16-20.
20. P.A. Hanna and J. Jankovic, Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response, Neurology 50 (1998), 1624-1629.
21. M. Jahanshahi and C.D. Marsden, Psychological functioning before and after treatment of torticollis with botulinum toxin, J Neural Neurosurg Psychiatry 55 (1992), 229-231.
22. J. Jankovic, S. Leder, D. Warner and K. Schwartz, Cervical dystonia: clinical findings and associated movement disorders, Neurology 41 (1991), 1088-1091.
23. M.F. Lew, B.T. Adornato and D.D. Duane et al., Botulinum toxin type B: a double blind, randomized, placebo-controlled, safety and efficacy study in cervical dystonia, Neurology 49 (1997), 701-707.
24. D.H. Lowenstein and M.J. Aminoff, The clinical course of spasmodic torticollis, Neurology 38 (1988), 530-532.
25. J.G. Nutt, M.D. Muenter, L.J. Melton III, A. Aronson and L.T. Kurland, Epidemiology of dystonia in Rochester, Minnesota, Adv Neurol 50 (1988), 361-365.
26. K. Oguma, Y. Fujinaga and K. Inouek et al., Structure and function of Clostridium botulinum toxins, Microbiol Immunol 39 (1995), 161-168.
27. M. Porta, Botulinum toxin type A injections for myofascial pain syndrome and tension-type headache, Eur J Neurol 6(4) (1999), S103-S109.
28. M.A. Relja and M. Korsic, Treatment of tension-type headache by injections with botulinum toxin type A: a double-blind placebo-controlled study, Neurology 52(6 suppl 2) (1999), 183-186.
29. G. Sakaguchi, Clostridium botulinum toxins, Pharmacol Ther 19 (1983), 165-194.
30. S. Silberstein, N. Mathew and J. Saper et al., Botulinum toxin type A as a migraine preventive treatment, Headache 40 (2000), 445-450.
31. J.K.C. Tsui, Botulinum toxin as a therapeutic agent, Pharmacol Ther 72 (1996), 13-24.
32. A.H. Wheeler, P. Goolkasian and S.S. Gretz, A randomized, double blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome, Spine 23 (1998), 1662-1667.